The outcomings of a post hoc analysis from CheckMate 026, nonetheless, implied that the application of TMB as a predictive biomarker instead of or in addition to PD-L1 expression may be conducive to selecting patients with advanced NSCLC who embrace great possibility of reaping benefits of immunotherapy (35). This evidence concerns the gene CD274 and non-small cell lung carcinoma.